Propranolol as a novel treatment for congenital visceral haemangioma.
Haemangiomas are the most common soft tissue tumours in infancy, occurring in approximately 5-10% of 1-year-old children. Current drug-based therapeutic options for large haemangiomas include corticosteroids, α-interferon and vincristin, all of which can result in harmful side effects. Recently, promising results have been reported using the non-cardio-selective β-blocker propranolol for the treatment of cutaneous capillary haemangiomas, in which a spectacular size reduction was observed during the first 7 days of treatment. We here report a similar significant and rapid inhibitory effect of propranolol on the growth of a viscerally located congenital haemangioma.
Vanlander
Arnaud
A
Neonatal Intensive Care Unit, AZ-St-Jan Bruges-Ostend AV, Bruges, Belgium.
Decaluwe
Wim
W
Vandelanotte
Michel
M
Van Geet
Christel
C
Cornette
Luc
L
D000008:Abdominal Neoplasms / Q000151:congenital* / Q000188:drug therapy* / Q000473:pathology; D006391:Hemangioma / Q000151:congenital* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011433:Propranolol / Q000627:therapeutic use*; D014470:Umbilical Cord / Q000187:drug effects / Q000473:pathology; D054079:Vascular Malformations / Q000188:drug therapy / Q000473:pathology; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents; D011433:Propranolol